摘要
目的评估局部晚期宫颈癌患者及其新辅助化疗前后的肾功能。方法选取45例局部晚期宫颈癌患者,分别取患者新辅助化疗前后血清和30例正常对照者血清,同时测定血清胱抑素C(CysC),检测采用胶乳增强免疫透射比浊法;尿素氮(BUN),采用速率脲酶法;肌酐(Scr),采用碱性苦味酸法测定。结果局部晚期宫颈癌患者血清CysC水平显著高于正常对照者,新辅助化疗前后CysC水平差异有统计学意义(P<0.05),而BUN、Scr的比较差异无统计学意义(P>0.05)。结论局部晚期宫颈癌患者均存在不同程度的肾功能损害,血清CysC是评价局部晚期宫颈癌患者新辅助化疗过程中肾功能早期损害的良好临床指标。
Objective To evaluate the renal function in patients with locally advanced cervical cancer patients throughout neoadjuvant chemotherapy. Methods Serums from 45 patients with locally advanced cervical cancer, taken before and after rleoadjuvant chemotherapy, and 30 normal control serums were collected. Serum cystatin C （CysC） , BUN and Scr were assessed by latex enhanced immune transmission turbidity, rate of urea enzymatic and alkaline picric acid methods, respectively. Results CysC was significantly higher in patients with locally advanced cervical cancer than those in normal control group, also significant difference was revealed between before and after neoadjuvant chemotherapy （ P 〈 0.05 ）. Conclusion Locally advanced cervical cancer patients have different degrees of renal dysfunction, whereas serum CysC provides good clinical indicator to evaluate renal function with early damage during the process of neoadjuvant chemo- therapy.
出处
《广东医学》
CAS
CSCD
北大核心
2012年第6期768-770,共3页
Guangdong Medical Journal
关键词
胱抑素C
肾功能
宫颈癌
新辅助化疗
cystatin C
renal function
cervical cancer
neoadjuvant chemotherapy
